LARKSPUR, Calif.–(BUSINESS WIRE)–#GBMAGILE–Global Coalition for Adaptive Research (GCAR), a 501(c)(3) non-profit research organization, announced that together with their patient/advocacy and pharma/biotech partners, they will ring the Nasdaq Stock Market Closing Bell today to spotlight National Brain Tumor Awareness Month and their innovative, global brain tumor trial called GBM AGILE.
The GBM AGILE trial, lead by GCAR, is a multi-stakeholder adaptive platform trial for patients with glioblastoma (GBM) – the deadliest of malignant primary brain tumors. GBM accounts for 48% of all primary brain cancers and has a median survival rate of less than 15 months, with only 3 treatments approved in the last 40 years.
GCAR is joined by their GBM AGILE partners: Bayer, Kazia Therapeutics, Kintara Therapeutics, Vigeo Therapeutics, Biohaven, Polaris Pharmaceuticals, National Brain Tumor Society, National Foundation for Cancer Research, Asian Fund for Cancer Research, and Cure Brain Cancer Foundation.
“We are honored to ring the Nasdaq closing bell alongside our GBM AGILE partners, patients, caregivers, and physicians united to raise awareness of the critical, unmet need for new treatment options for patients with brain tumors,” said Dr. Meredith Buxton, CEO and President of GCAR. “Innovative trials like GBM AGILE accelerate drug development through a more cost-effective and rapid path to market approval; however, more investment is needed to advance new treatment options and to drive breakthroughs in patient care.”
Each year, approximately 300,000 people worldwide are diagnosed with primary brain tumors. May is National Brain Tumor Awareness Month, a time to support and magnify the voice of the brain tumor community and draw attention to the critical, unmet need for faster and better treatment options. #GoGrayinMay
About Global Coalition for Adaptive Research (GCAR)
Global Coalition for Adaptive Research (GCAR) is a 501(c)(3) non-profit corporation uniting biotech/pharma, physicians, clinical researchers, advocacy and philanthropic organizations, health authorities, and other key stakeholders in healthcare. Together, GCAR and its partners expedite the discovery and development of treatments for patients with rare and deadly diseases. GCAR leads and implements innovative and complex trials including master protocols and platform trials and is the sponsor of GBM AGILE, a patient-centric adaptive platform trial for patients with GBM – the deadliest of malignant primary brain tumors. Key advocacy partners for the GBM AGILE trial effort include the National Brain Tumor Society, National Foundation for Cancer Research, Asian Fund for Cancer Research, and Cure Brain Cancer Foundation, non-profit organizations working together to provide philanthropic support and assist in communicating with patients and families. We invite others to support this innovative approach to brain tumor treatment development. To learn more about GCAR and its initiatives, visit gcaresearch.org.
Contacts
Global Coalition for Adaptive Research
Rachel Rosenstein-Sisson
media@gcaresearch.org
